Luke Roush Named Vice President of Global Marketing at TransEnterix
Roush is responsible for setting and executing TransEnterix’s worldwide marketing and commercialization strategy, which includes communicating the benefits of the company’s SPIDER® Surgical System to hospitals, surgeons and patients.
Research Triangle Park, NC, May 14, 2010 --(PR.com)-- Luke M. Roush has been named vice president of global marketing at TransEnterix.
Roush is responsible for setting and executing TransEnterix’s worldwide marketing and commercialization strategy, which includes communicating the benefits of the company’s SPIDER® Surgical System to hospitals, surgeons and patients.
Distributed earlier this year to select hospitals, the SPIDER Surgical System combines flexible, catheter-based technology with the familiar procedures of traditional laparoscopic surgery, creating an entirely new class of surgery called flexible laparoscopy. With the SPIDER System and future product innovations, this new class of surgery promises to change how patients are treated for a wide variety of disease states.
“TransEnterix’s vision of transforming the surgical experience for patients and surgeons alike is an ambitious one,” said Todd M. Pope, president and CEO. “Luke possesses the strategic thinking and tactical know-how to help bring that vision to fruition as we address surgeon and patient needs in a worldwide, multi-billion dollar marketplace.”
Roush was just honored by the Triangle Business Journal with its “40 Under 40” Leadership Award, which spotlights top Triangle-area professionals under the age of 40 who excel in their fields, show dynamic leadership and invest time and talent in their communities.
Before joining TransEnterix, Roush served as chief operating officer and vice president of business development at Liquidia, a privately held biopharmaceutical company based in the Research Triangle Park. There, he helped focus the company’s platform technology on the life sciences arena, and managed the organization’s cross-functional operating plan. He also helped secure more than $30 million in venture capital, corporate partnership and government grant funding.
From his tenure at Liquidia, Roush has two patents pending for using medical devices to help deliver nanoparticle therapeutics. Roush has a third patent pending for designing a resheathable nitinol stent for intracranial use, which he authored while leading the hemorrhagic stroke franchise at Boston Scientific Neurovascular.
Philanthropically, Roush serves as vice chairman of the board for the non-profit Ten Thousand Villages, which Forbes magazine recently recognized as one of the world’s most ethical companies. He also serves as a board member at the non-profit organization TROSA, which helps people recover from drug and alcohol addiction and operates the state’s largest state-licensed residential therapeutic community.
Roush holds a master’s degree in business administration from the Fuqua School of Business at Duke University, where he also earned his bachelor’s of arts degree, graduating summa cum laude with high distinction. Roush financed his undergraduate tuition with an athletic scholarship, playing varsity football for four seasons. Upon graduation, Roush was endorsed by Duke University as a Rhodes Scholar candidate.
TransEnterix, a fast-growing medical device company, partners with leading medical thought-leaders to rapidly develop pioneering technologies that advance minimally invasive surgery. The company has secured $75 million in venture capital funding.
###
Roush is responsible for setting and executing TransEnterix’s worldwide marketing and commercialization strategy, which includes communicating the benefits of the company’s SPIDER® Surgical System to hospitals, surgeons and patients.
Distributed earlier this year to select hospitals, the SPIDER Surgical System combines flexible, catheter-based technology with the familiar procedures of traditional laparoscopic surgery, creating an entirely new class of surgery called flexible laparoscopy. With the SPIDER System and future product innovations, this new class of surgery promises to change how patients are treated for a wide variety of disease states.
“TransEnterix’s vision of transforming the surgical experience for patients and surgeons alike is an ambitious one,” said Todd M. Pope, president and CEO. “Luke possesses the strategic thinking and tactical know-how to help bring that vision to fruition as we address surgeon and patient needs in a worldwide, multi-billion dollar marketplace.”
Roush was just honored by the Triangle Business Journal with its “40 Under 40” Leadership Award, which spotlights top Triangle-area professionals under the age of 40 who excel in their fields, show dynamic leadership and invest time and talent in their communities.
Before joining TransEnterix, Roush served as chief operating officer and vice president of business development at Liquidia, a privately held biopharmaceutical company based in the Research Triangle Park. There, he helped focus the company’s platform technology on the life sciences arena, and managed the organization’s cross-functional operating plan. He also helped secure more than $30 million in venture capital, corporate partnership and government grant funding.
From his tenure at Liquidia, Roush has two patents pending for using medical devices to help deliver nanoparticle therapeutics. Roush has a third patent pending for designing a resheathable nitinol stent for intracranial use, which he authored while leading the hemorrhagic stroke franchise at Boston Scientific Neurovascular.
Philanthropically, Roush serves as vice chairman of the board for the non-profit Ten Thousand Villages, which Forbes magazine recently recognized as one of the world’s most ethical companies. He also serves as a board member at the non-profit organization TROSA, which helps people recover from drug and alcohol addiction and operates the state’s largest state-licensed residential therapeutic community.
Roush holds a master’s degree in business administration from the Fuqua School of Business at Duke University, where he also earned his bachelor’s of arts degree, graduating summa cum laude with high distinction. Roush financed his undergraduate tuition with an athletic scholarship, playing varsity football for four seasons. Upon graduation, Roush was endorsed by Duke University as a Rhodes Scholar candidate.
TransEnterix, a fast-growing medical device company, partners with leading medical thought-leaders to rapidly develop pioneering technologies that advance minimally invasive surgery. The company has secured $75 million in venture capital funding.
###
Contact
TransEnterix
Karen Stinneford
919.833.9102
www.sinclair-co.com
Contact
Karen Stinneford
919.833.9102
www.sinclair-co.com
Categories